Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 5.18% and Operating profit at 18.80% over the last 5 years
2
Positive results in Mar 26
3
With ROE of 9.23%, it has a fair valuation with a 1.27 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,683 Million (Small Cap)
12.00
NA
4.10%
-0.21
9.23%
1.52
Revenue and Profits:
Net Sales:
213 Million
(Quarterly Results - Jun 2026)
Net Profit:
68 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
56.05%
0%
56.05%
6 Months
55.02%
0%
55.02%
1 Year
47.96%
0%
47.96%
2 Years
83.43%
0%
83.43%
3 Years
37.98%
0%
37.98%
4 Years
77.55%
0%
77.55%
5 Years
54.52%
0%
54.52%
Hunan Hansen Pharmaceutical Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.18%
EBIT Growth (5y)
18.80%
EBIT to Interest (avg)
74.19
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.15
Sales to Capital Employed (avg)
0.44
Tax Ratio
17.31%
Dividend Payout Ratio
76.20%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
9.86%
ROE (avg)
9.10%
Valuation key factors
Factor
Value
P/E Ratio
12
Industry P/E
Price to Book Value
1.14
EV to EBIT
10.33
EV to EBITDA
9.43
EV to Capital Employed
1.18
EV to Sales
2.18
PEG Ratio
0.41
Dividend Yield
5.45%
ROCE (Latest)
11.43%
ROE (Latest)
9.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
212.90
263.20
-19.11%
Operating Profit (PBDIT) excl Other Income
49.50
67.60
-26.78%
Interest
0.20
0.30
-33.33%
Exceptional Items
0.40
0.60
-33.33%
Consolidate Net Profit
68.20
38.40
77.60%
Operating Profit Margin (Excl OI)
184.40%
217.90%
-3.35%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is -19.11% vs -11.68% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 77.60% vs -66.78% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,026.80
992.70
3.44%
Operating Profit (PBDIT) excl Other Income
270.00
278.00
-2.88%
Interest
2.00
2.90
-31.03%
Exceptional Items
1.80
2.10
-14.29%
Consolidate Net Profit
198.10
220.20
-10.04%
Operating Profit Margin (Excl OI)
222.50%
238.30%
-1.58%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.44% vs 5.17% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -10.04% vs 7.41% in Dec 2024
About Hunan Hansen Pharmaceutical Co. Ltd. 
Hunan Hansen Pharmaceutical Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






